BRAF and melanoma: 12.8% in treatment-refractory metastatic melanoma, 28% in advanced melanoma, 40% in melanoma treated in combination with ipilimumab, 20% in nivolumab followed by iplimumab, 40% in previously untreated melanoma without BRAF mutation, 57.6% (nivolumab plus iplimumab) versus 19% (ipilimumab) versus 43.7% (nivolumab) in untreated stage III or IV melanoma